Discussion
Nearly half of ANCA-associated vasculitis (AAV) patients treated with rituximab developed hypogammaglobulinemia (HGG), or low blood levels of antibodies, according to a population-based Swedish study. While antibodies normally help fight infections, the occurrence of HGG was not associated with an increased risk of severe infections among rituximab-treated patients…